Evidence
NanoACi is grounded in established component technologies and a new way of bringing them together. This page separates what is already published from what the complete technique still needs to prove.
What is known
Autologous cartilage micrografts have prospective observational data in knee osteoarthritis. ChondroFiller has published technical and clinical use across cartilage lesions. Platelet-rich plasma is a widely used autologous platelet concentrate with a general evidence base in joints and soft tissue.
What remains open
There is not yet a peer-reviewed NanoACi-specific consecutive series. The 100-case programme exists to measure benefit, safety, durability, patient selection and failure—not to assume them.
Evidence library
Selected sources are grouped by the biological role they inform, not presented as proof of the complete NanoACi protocol.
PRP is a widely used autologous platelet concentrate with a general evidence base in joints and soft tissue. The complete NanoACi protocol has no direct trial yet.
NanoACi 100
Freeze the technique, indications, outcomes and follow-up plan before analysis.
Capture 100 consecutive cases, including complications, revisions and non-responders.
Use transparent methods and, where practical, independent statistical review.
Submit the work to appropriate cartilage, orthopaedic and regenerative-medicine meetings.
Move from technique paper to outcomes series, then comparative and multicentre work.